While Apixaban’s dual anticoagulant and anti-inflammatory profile is therapeutically valuable, its weaker persistence within the S100A9 binding pocket suggests that its immunomodulatory effect may be secondary or supportive rather than central in sepsis management [63]. The gene discussed is S100A9; the disease is Sepsis.